Story perspectives

Eli Lilly Invests $55M in Oral Weight-Loss Drug Partnership

1/7/2026

Summary

Story summary

Eli Lilly and Company partner with Nimbus Therapeutics to develop an oral weight-loss treatment, advancing Lilly's obesity-drug strategy.
The deal includes an upfront payment of $55 million and milestone payments totaling $1.3 billion.
The collaboration builds on Lilly's earlier cardiometabolic-diseases partnership.
Competition grows as the Food and Drug Administration (FDA) approves an oral obesity drug, prompting Lilly to strengthen its pipeline, though success depends on trial execution and market dynamics.

History

Historical Context

Eli Lilly, founded in 1876, has a history of innovation, notably producing the first commercially available insulin in 1923 through collaboration with University of Toronto scientists. The company has expanded significantly, acquiring various firms, including ImClone for $6.5 billion in 2008. In 2015, Eli Lilly's strategic acquisitions, like Ventyx Biosciences, reflect ongoing efforts to enhance its competitive edge in autoimmune and obesity treatments.

1 of 2

Story summary

Eli Lilly and Company partner with Nimbus Therapeutics to develop an oral weight-loss treatment, advancing Lilly's obesity-drug strategy.
The deal includes an upfront payment of $55 million and milestone payments totaling $1.3 billion.
The collaboration builds on Lilly's earlier cardiometabolic-diseases partnership.
Competition grows as the Food and Drug Administration (FDA) approves an oral obesity drug, prompting Lilly to strengthen its pipeline, though success depends on trial execution and market dynamics.

1 / 2